- Home
- FROG vs RYTM Comparison
FROG vs RYTM Comparison
Compare FROG & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FROG
- RYTM
- Stock Information
- Founded
- FROG 2008
- RYTM 2008
- Country
- FROG United States
- RYTM United States
- Employees
- FROG N/A
- RYTM N/A
- Industry
- FROG Computer Software: Prepackaged Software
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- FROG Technology
- RYTM Health Care
- Exchange
- FROG Nasdaq
- RYTM Nasdaq
- Market Cap
- FROG 3.6B
- RYTM 4.3B
- IPO Year
- FROG 2020
- RYTM 2017
- Fundamental
- Price
- FROG $39.83
- RYTM $86.70
- Analyst Decision
- FROG Strong Buy
- RYTM Strong Buy
- Analyst Count
- FROG 19
- RYTM 13
- Target Price
- FROG $41.00
- RYTM $88.77
- AVG Volume (30 Days)
- FROG 922.3K
- RYTM 972.0K
- Earning Date
- FROG 08-07-2025
- RYTM 08-05-2025
- Dividend Yield
- FROG N/A
- RYTM N/A
- EPS Growth
- FROG N/A
- RYTM N/A
- EPS
- FROG N/A
- RYTM N/A
- Revenue
- FROG $450,584,000.00
- RYTM $136,863,000.00
- Revenue This Year
- FROG $19.79
- RYTM $37.56
- Revenue Next Year
- FROG $15.14
- RYTM $74.99
- P/E Ratio
- FROG N/A
- RYTM N/A
- Revenue Growth
- FROG 21.66
- RYTM 48.88
- 52 Week Low
- FROG $22.91
- RYTM $40.61
- 52 Week High
- FROG $45.10
- RYTM $94.80
- Technical
- Relative Strength Index (RSI)
- FROG 39.32
- RYTM 76.93
- Support Level
- FROG $41.18
- RYTM $64.65
- Resistance Level
- FROG $42.78
- RYTM $94.80
- Average True Range (ATR)
- FROG 1.38
- RYTM 3.47
- MACD
- FROG -0.39
- RYTM 2.75
- Stochastic Oscillator
- FROG 3.40
- RYTM 76.18
About FROG JFrog Ltd.
JFrog Ltd provides an end-to-end, hybrid, universal DevOps Platform that powers and controls the software supply chain, enabling organizations to continuously and securely deliver software updates across any system. Its product portfolio includes JFrog Artifactory; JFrog Pipelines; JFrog Xray; JFrog Distribution; JFrog Artifactory Edge; JFrog Mission Control and JFrog Insight. Geographically, it derives a majority of revenue from Israel and also has its presence in United States, India and other regions.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.